Evidence map›Paper›PMID 38081369›Full record

ArticleBiochemical pharmacology2024

Unlocking the protective potential of the angiotensin type 2 receptor (AT

Peter Abadir, Caglar Cosarderelioglu, Mahendra Damarla, Alla Malinina, Dustin Dikeman, Ruth Marx, Monica M Nader, Michael Abadir, Jeremy Walston, Enid Neptune

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis.Seminars in respiratory and critical care medicine · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Peter AbadirJohns Hopkins University, Division of Geriatrics Medicine and Gerontology, Department of Medicine, USA. Electronic address: Pabadir1@jhmi.edu.
Caglar CosardereliogluJohns Hopkins University, Division of Geriatrics Medicine and Gerontology, Department of Medicine, USA.
Mahendra DamarlaJohns Hopkins University, Division of Pulmonary and Critical Care Medicine, USA.
Alla MalininaJohns Hopkins University, Division of Pulmonary and Critical Care Medicine, USA.
Dustin DikemanJohns Hopkins University, Division of Pulmonary and Critical Care Medicine, USA.
Ruth MarxJohns Hopkins University, Division of Geriatrics Medicine and Gerontology, Department of Medicine, USA.
Monica M NaderJohns Hopkins University, Division of Geriatrics Medicine and Gerontology, Department of Medicine, USA; Urbana High School, USA.
Michael AbadirUniversity of Maryland College Park, USA.
Jeremy WalstonJohns Hopkins University, Division of Geriatrics Medicine and Gerontology, Department of Medicine, USA.
Enid NeptuneJohns Hopkins University, Division of Pulmonary and Critical Care Medicine, USA. Electronic address: Eneptune@jhmi.edu.
Johns Hopkins University · USUniversity of Maryland, College Park · US

Funding

Technological Assessment and Solutions Core - RC4P30AG021334 · NIA · JOHNS HOPKINS UNIVERSITY · PI Jeremy D Walston · 2003 to 2026
$33.2M
Strategies for Angiotensin Receptor Blocker Mediated Tissue RepairR01HL154343 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NEPTUNE, ENID R · 2020 to 2023
$2.5M
Age Related Change in Mitochondrial Angiotensin System and Mitochondrial DeclineR01AG046441 · NIA · JOHNS HOPKINS UNIVERSITY · PI ABADIR, PETER M. · 2014 to 2018
$2.3M
NHLBI NIH HHS R01 HL154343NIA NIH HHS P30 AG021334NIA NIH HHS R01 AG046441
6 · The paper itself

Abstract

Despite its known importance in the cardiovascular system, the specific role and impact of the angiotensin type 2 receptor (AT

Indexed as

Acute Lung InjuryReceptor, Angiotensin, Type 2Angiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsAnimalsMiceReceptor, Angiotensin, Type 1Angiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Acute lung injuryAngiotensin type 2 receptorHyperoxic acute lung injuryLung RASRenin-angiotensin signaling system

Identifiers

PMID38081369
PMCPMC10880333
OpenAlexW4389503615

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.